Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to $6.8 million.

  • TriSalus Life Sciences' Cost of Revenue rose 1142.07% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year increase of 1355.95%. This contributed to the annual value of $25.8 million for FY2024, which is 5169.07% up from last year.
  • TriSalus Life Sciences' Cost of Revenue amounted to $6.8 million in Q3 2025, which was up 1142.07% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, TriSalus Life Sciences' Cost of Revenue registered a high of $7.2 million during Q2 2025, and its lowest value of $3.0 million during Q3 2022.
  • Over the past 4 years, TriSalus Life Sciences' median Cost of Revenue value was $6.0 million (recorded in 2024), while the average stood at $5.4 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 10581.72% in 2024, then surged by 70.29% in 2025.
  • Quarter analysis of 4 years shows TriSalus Life Sciences' Cost of Revenue stood at $3.9 million in 2022, then skyrocketed by 45.29% to $5.6 million in 2023, then increased by 25.09% to $7.0 million in 2024, then decreased by 2.44% to $6.8 million in 2025.
  • Its Cost of Revenue was $6.8 million in Q3 2025, compared to $7.2 million in Q2 2025 and $6.7 million in Q1 2025.